医学
醋酸阿比特龙酯
前列腺癌
强的松
危险系数
安慰剂
雄激素剥夺疗法
内科学
中期分析
泌尿科
临床终点
肿瘤科
外科
随机对照试验
癌症
置信区间
病理
替代医学
作者
Karim Fizazi,NamPhuong Tran,Luis Fein,Nobuaki Matsubara,A. Rodrı́guez-Antolı́n,B. Yа. Alekseev,Mustafa Özgüroğlu,Dingwei Ye,Susan Feyerabend,Andrew Protheroe,Peter De Porre,Thian Kheoh,Youn C. Park,Mary B. Todd,Kim N.
标识
DOI:10.1056/nejmoa1704174
摘要
The addition of abiraterone acetate and prednisone to androgen-deprivation therapy significantly increased overall survival and radiographic progression-free survival in men with newly diagnosed, metastatic, castration-sensitive prostate cancer. (Funded by Janssen Research and Development; LATITUDE ClinicalTrials.gov number, NCT01715285 .).
科研通智能强力驱动
Strongly Powered by AbleSci AI